LOX and neoplasm: These results, together with our already published observations [21] showing that inhibition of ACSL4 expression in MDA-MB-231 transforms the cells into a non-aggressive phenotype, strongly suggests that the effect of rosiglitazone in MDA-MB-231 cell proliferation or the effect on tumor growth of rosiglitazone in combination with LOX and COX inhibitors results from ACSL4 inhibition and that the effect of rosiglitazone appears to be cell type-specific due to the difference in signaling pathways regulating cell growth and survival.